InspireMD (NYSE:NSPR) posted second-quarter results this week that beat the earnings consensus on Wall Street but missed revenue estimates.
The Tel Aviv, Israel-based carotid stenting company reported losses of $3.5 million, or -46¢ per share, on sales of $1.03 million for the three months ended June 30, for a sales growth of 231.63% compared with Q2 2020.
InspireMD’s earnings of -46¢ were 17¢ ahead of The Street, where analysts were looking for $1.1 million in sales.
“We are pleased with our second-quarter results that showed strong procedural recovery and market demand of CGuard EPS. Our ultimate goal is to change the standard of care in the treatment of carotid artery disease away from surgical endarterectomy to the minimally invasive use of CGuard EPS carotid stent system,” CEO Marvin Slosman said in a news release.
The company did not offer financial guidance for the 2021 year.
Shares in NSPR were up 4.04% to $4.12 apiece in pre-market trading.